Researchers at Aalto University in Finland have developed an experimental laser heat treatment designed to prevent blindness caused by dry age-related macular degeneration [1, 2].
The breakthrough could offer a preventative solution for millions of older adults by addressing retinal decay before permanent vision loss occurs [1, 2].
The treatment utilizes near-infrared light to gently warm retinal tissue [1, 2]. This controlled heating process is intended to activate the eye's own natural cleanup and repair mechanisms [1, 2]. By triggering these biological responses, the therapy aims to clear debris and restore health to the retina before major damage becomes irreversible [1, 2].
Dry age-related macular degeneration is a leading cause of blindness in the elderly [1, 2]. Unlike some other forms of vision loss, this condition often involves a slow degradation of the central retina that is difficult to treat once the cells have died [1, 2]. The Finnish team is focusing on the early stages of the disease, a window where the eye remains responsive to therapeutic intervention [1, 2].
The research was highlighted in a report released Tuesday, May 26, 2026 [1]. The method differs from traditional laser surgeries that typically cauterize or destroy tissue; instead, this approach uses heat as a catalyst for cellular regeneration [1, 2].
While the treatment remains experimental, the goal is to provide a non-invasive way to maintain ocular health into old age [1, 2]. The researchers are working to refine how the near-infrared light interacts with the retinal layers to ensure maximum efficacy without risking thermal damage to the surrounding eye structure [1, 2].
“The treatment utilizes near-infrared light to gently warm retinal tissue.”
This research represents a shift toward preventative regenerative medicine in ophthalmology. By focusing on 'cleaning' the retina via heat-induced biological triggers rather than replacing lost tissue, the treatment could potentially extend the period of functional vision for aging populations if it passes clinical trials.





